Zurich, Switzerland

Burkhard Springer

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Burkhard Springer. Retrieved from https://idiyas.com/inventor/burkhard-springer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,513 
Other
 patents

Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Burkhard Springer: Innovator in Mycobacterial Therapy

Introduction

Burkhard Springer is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of immunotherapy through his innovative work with mycobacteria. His research focuses on developing mutant strains that can be utilized in therapeutic applications.

Latest Patents

Burkhard Springer holds a patent for "Mutant mycobacteria for use in therapy." This invention pertains to recA mutant mycobacteria, particularly those from mycobacterial species that are members of the complex, such as BCG. These mutant mycobacteria serve as immunotherapeutic agents and vaccines for treating various disorders, including tuberculosis. He has 1 patent to his name.

Career Highlights

Throughout his career, Burkhard Springer has demonstrated a commitment to advancing medical science. His work has the potential to impact the treatment of infectious diseases significantly. He continues to explore innovative solutions in the field of immunotherapy.

Collaborations

Burkhard has collaborated with professionals such as Kay Colston, a Legal Representative, and Eric Boettger. These collaborations enhance the development and application of his inventions.

Conclusion

Burkhard Springer is a pioneering inventor whose work with mutant mycobacteria is paving the way for new therapeutic approaches. His contributions to immunotherapy are noteworthy and hold promise for future medical advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…